Shares of WeedMD (TSXV:WMD,OTCQX:WDDMF) jumped last week after a dual financing and acquisition announcement on November 29. Now the company says it is looking to move forward on “financially stable footing” in 2020.
The Ontario-based firm shocked investors with the simultaneous release of its results for the third quarter and its plans to acquire Starseed Holdings in an all-stock, arm’s length deal valued at C$78 million. Along with the acquisition, WeedMD also got its hands on a C$25 million equity investment from the Laborers’ Pension Fund of Central and Eastern Canada, Starseed’s largest backer.
In an email statement to the Investing News Network (INN), Keith Merker, CEO of WeedMD, said the firm is currently focused on closing its acquisition of Starseed, set to be completed sometime in December, and on scaling up production.
The influx of cash comes at a notoriously difficult time for cannabis companies, which are struggling to find capital while dealing with volatility across the sector.
“We’re fortunate that the timing has provided us with a relatively risk-free and creative way to inject fresh capital into our business,” Merker told INN, adding that the firm has no other plans to look for capital for now, since it currently boasts a pro forma cash balance of about C$56 million.
Starseed has a partnership with Canada’s largest construction union, the Laborers’ International Union of North America (LiUNA), through which it offers medical cannabis as a fully covered benefit to LiUNA’s more than 100,000 members and retirees.
WeedMD’s initial double-barreled announcement, and the resulting investor confusion, prompted Merker to write an open letter discussing the headwinds that led the company to its deal with Starseed and its newfound financing.
“Capital has become scarce and expensive, and the adult-use market has been slower to ramp and at thinner margins for licensed producers than many originally anticipated,” Merker told investors in the letter. “These market pressures have forced us, like many others, to reevaluate our business.”
The “arm’s length” part of the deal comes from WeedMD’s longstanding relationship with Starseed as a supplier, Merker said, adding that WeedMD has been in talks with Starseed for a more permanent partnership for some time.
As a part of its results for Q3, WeedMD reported an expected outdoor yield of 8 tons of dried cannabis, which came in under its anticipated weight. Merker attributed the lower yield to inexperience with outdoor growing during an earnings call with investors and analysts.
Revenue generation also missed expectations for Q3 at C$6.7 million, down from the nearly C$8 million in Q2 of this year.
Merker chalked up the volatile market reaction to the timing and packaging of the transaction, the quarterly results and the yield that missed the mark. Now, he said, he expects investors will “recalibrate their investment thesis” and consider WeedMD’s augmented position in the recreational cannabis space and new access to the insured benefit channel for medical cannabis.
“Starseed brings a critical part of this business equation that has been difficult for the market to find: consistent, sticky distribution channels with direct access to fully covered and insured patients,” said Merker during the earnings call.
Despite the mixed bag of news from the company, Merker said the transaction is a crucial part of WeedMD’s continued growth.
“The benefit to both WeedMD and Starseed is that we are now providing Starseed’s patients with a consistent supply of medical-grade cannabis. And since we’ll be one company, we don’t envision that much of a transition will be required,” Merker told INN.
Shares of WeedMD took a dip over the trading session on Tuesday (December 10), falling just over 3 percent during the trading day.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”
HempFusion Wellness Submits Novel Foods Dossier to the United Kingdom’s Regulatory Food Safety Agency
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/